Altogether, these data indicated docetaxel-based chemohormonal therapy can trigger DNA release into the cytosol, thereby activating the cGAS/STING pathway, which leads to IFN-stimulated genes response in prostate cancer cells. Here, IFNA1 is linked to prostate carcinoma.